RELPI
4.1.2022 15:02:06 CET | Business Wire | Press release
The Real Estate Limited Partner Institute (RELPI) today announced the expansion of its compelling Interests Aligned programs to Europe and the United Kingdom with the appointment of institutional real estate investment and media professional Arno Van Grondelle as CEO of RELPI Europe.
RELPI’s intimate, focused and curated local meet-ups foster open conversation and deep relationships among leading stakeholders in the investment and allocation of capital in real estate. The series was formally launched in 2021 with events in Austin, New York and Philadelphia, and was met with an overwhelming interest and attendance. In addition to the expansion into Europe and the United Kingdom, RELPI has announced events in Chicago, Cleveland, Los Angeles, San Francisco and New York so far in 2022.
“Our success and expansion reflect the pent-up demand for in-person gatherings and virtual meetings of informed, high-level executives to share insights, ideas and transparent conversations devoted to best practices in institutional real estate asset allocation and investment,” said RELPI’s CEO and Executive Director Jonathan Schein. “In less than six months, the RELPI community has grown to include more than 125 pension funds, endowments foundations and family offices, as well as more than 50 fund managers.”
The addition of Arno Van Grondelle as CEO of RELPI Europe will accelerate this expansion. Mr. Van Grondelle brings extensive knowledge and leadership experience from his many years working in the institutional real estate investment and media industries. Most recently he served as Managing Director of Europe at Institutional Real Estate Inc., responsible for client relations, business development and sales for Institutional Real Estate Europe magazine. He previously served as International Sales Director at PropertyEU, where he was responsible for the sales of PropertyEU's comprehensive media portfolio, including PropertyEU magazine and EXPO Real's Preview and Daily News.
"Arno’s wealth of knowledge, experience and relationships in the European investor and LP arena will solidify RELPI’s fast mover status in the industry,” said Mr. Schein "His professionalism and market acumen will make a great addition to our growing platform designed to connect key players for the mutual benefit of the dynamic private equity real estate investment and capital industries.”
“I am very excited to join RELPI and further build this community in Europe,” said Mr. Van Grondelle. “We are dedicated to bringing together real estate institutional investors, fund managers, operating companies and those organizations allied to the industry on a local, regional and global scale.”
The Interests Aligned series are designed to be streamlined and efficient (just three hours long) with a strong emphasis on social networking, offering RELPI’s unique value proposition – intimate, ultrahigh-value gatherings, in a streamlined, economically effective manner, with “proximity” in mind.
For more information about the Interests Aligned series, to register or inquire about membership, please visit: www.RELPI.org
About RELPI
As an established producer of successful meetings, events and conferences devoted to the global institutional investment community for the commercial real estate class, with “proximity” as the prime value proposition, RELPI is perfectly positioned to deliver a best-of-both-worlds solution: intimate, ultrahigh-value gatherings in a streamlined, economically effective way. From “virtual salons” and global summits focused on investors in all major global markets, to emerging manager programs and even “private label,” bespoke roundtables, RELPI is enabling tomorrow’s business connectivity today.
https://www.relpi.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005129/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom